BIOLITE, INC.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Subsidiary, Holding
- Established
- 2009-10-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.bioliteenergy.com
PDC-1421 Treatment in Adult Patients With ADHD
Phase 2
Completed
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PlaceboDrug: PDC-1421 Capsule
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05202327
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Cheng Hsin General Hospital, Taipei, Taiwan
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
Phase 1
Not yet recruiting
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: PDC-1421 Capsule
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03833206
- Locations
- 🇺🇸
Cedars-Sinai Health System, Los Angeles, California, United States
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Phase 2
Not yet recruiting
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- Drug: BLEX 404 Oral Liquid
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02944955
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
Phase 1
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: BLEX 404 Oral Liquid
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02802423
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
Phase 2
Completed
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PDC-1421 Capsule
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02699086
- Locations
- 🇺🇸
UCSF Medical Center, San Francisco, California, United States
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
Phase 2
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: PDC-1421 CapsuleDrug: placebo
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02395978
- Locations
- 🇨🇳
Tri-Service General Hospital, Neihu Main Facility, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01774045
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath